Wall Street brokerages forecast that Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) will post $2.09 million in sales for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Tetraphase Pharmaceuticals’ earnings. The lowest sales estimate is $1.50 million and the highest is $3.31 million. Tetraphase Pharmaceuticals posted sales of $4.07 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 48.6%. The firm is scheduled to report its next quarterly earnings results on Thursday, November 1st.

According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year sales of $16.68 million for the current year, with estimates ranging from $8.00 million to $21.28 million. For the next financial year, analysts forecast that the firm will post sales of $22.61 million per share, with estimates ranging from $12.00 million to $46.03 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Tetraphase Pharmaceuticals.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.18. The business had revenue of $11.58 million during the quarter, compared to analyst estimates of $2.23 million. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%.

A number of equities research analysts have recently issued reports on TTPH shares. B. Riley upped their price target on Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, August 28th. Zacks Investment Research lowered Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. ValuEngine lowered Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, July 30th. Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Friday, August 3rd. Finally, WBB Securities upgraded Tetraphase Pharmaceuticals from a “speculative buy” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Thursday, September 6th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the stock. Tetraphase Pharmaceuticals currently has an average rating of “Hold” and an average price target of $6.41.

Shares of TTPH stock traded down $0.07 during trading hours on Friday, reaching $3.07. The company had a trading volume of 439,103 shares, compared to its average volume of 1,261,593. Tetraphase Pharmaceuticals has a 12-month low of $2.05 and a 12-month high of $7.98.

Institutional investors have recently modified their holdings of the stock. Flagship Harbor Advisors LLC purchased a new position in Tetraphase Pharmaceuticals in the second quarter worth approximately $104,000. Cubist Systematic Strategies LLC grew its position in Tetraphase Pharmaceuticals by 232.1% in the second quarter. Cubist Systematic Strategies LLC now owns 35,537 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 24,837 shares during the period. Canada Pension Plan Investment Board purchased a new position in Tetraphase Pharmaceuticals in the second quarter worth approximately $179,000. Dynamic Technology Lab Private Ltd grew its position in Tetraphase Pharmaceuticals by 322.1% in the first quarter. Dynamic Technology Lab Private Ltd now owns 76,108 shares of the biopharmaceutical company’s stock worth $234,000 after acquiring an additional 58,079 shares during the period. Finally, Alambic Investment Management L.P. purchased a new position in Tetraphase Pharmaceuticals in the first quarter worth approximately $356,000. Institutional investors own 40.94% of the company’s stock.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Recommended Story: NASDAQ Stock Market Explained

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.